Phase 2
Completed N=153
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Source: ClinicalTrials.gov NCT00500760 ↗Enrolled (actual)
153
Serious AEs
38.0%
Results posted
Aug 2014
Primary outcomePrimary: Local Regional Control Rate at 2 Years — 0.61; 0.68 proportion of paticipants
Summary
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Local Regional Control Rate at 2 Years |
0.61; 0.68 | — |
| SECONDARY Local Regional Control Rate at 6 Months and 12 Months |
0.70; 0.73; 0.66; 0.70 | — |
| SECONDARY Duration of Local-regional Control |
33.7; NA | 0.3106 |
| SECONDARY Progression-Free Survival |
NA; NA | 0.6069 |
| SECONDARY Overall Survival |
33.7; NA | 0.1223 |
| SECONDARY Percentage of Participants With an Objective Response at 6 Months |
71.26; 82.26 | 0.1737 |
| SECONDARY Percentage of Participants With a Complete Response at 6 Months |
20.69; 19.35 | 1.0000 |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of Stage III or IVa-b (M0) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (you must be well enough to receive chemoradiation therapy)
- You must be at least 18 years of age
- Your test results must show that your kidneys, liver and blood cells are working adequately and that, if you are female, you are not pregnant
- You must have measurable disease
Exclusion Criteria
- Cancer of the nasopharynx, sinus, salivary gland or skin
- History of another cancer (other than head and neck) unless treated with curative intent and with no evidence of disease for more than 3 years, with the exception of non-melanoma skin cancer or in situ cervical cancer
- Previous treatment with anti-endothelial growth factor receptor (EGFr) antibody therapy or EGFr inhibitors
- Previous treatment for head and neck cancer, with chemotherapy, surgery (except nodal sampling or biopsy) or radiotherapy
- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within one year before you join the study
- Chronic obstructive pulmonary disease (pneumonia or respiratory decompensation) resulting in hospitalization within 6 months of study screening
- History or evidence of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis)
- Major surgery within 28 days of screening
Data sourced from ClinicalTrials.gov (NCT00500760). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.